Validity of automated audiometry for hearing examination in patients with multidrug-resistant tuberculosis

F1000Res. 2021 Dec 14:10:1277. doi: 10.12688/f1000research.75090.2. eCollection 2021.

Abstract

Background: The objective of this study was to test the validity of automated audiometry as a method of hearing examination in patients with multidrug-resistant tuberculosis. Method s: This was a cross-sectional comparative study with a retrospective approach, using patient medical records. Patients with multidrug-resistant tuberculosis (MDR-TB) were recruited based-on medical records that met the inclusion and exclusion criteria at the Pulmonology outpatient unit, then referred to the Otorhinolaryngology outpatient unit of the Dr. Soetomo Academic Medical Center. The subjects' hearing function was measured with two different devices (automated audiometer and conventional audiometer) before being given anti-tuberculosis drug therapy (aminoglycoside injection) as ototoxicity monitoring from July to December 2019 period. Sensitivity and specificity analysis was used to assess the validity of the test. Results: A total of 36 patients (72 ears) were included. The comparison test results using the Mann-Whitney test showed that there were significant differences between automated audiometry and conventional audiometry in both ears. Analysis values were: sensitivity 80-97%, specificity 37-96%, positive predictive value 74-98%, and negative predictive value 59-96%. Conclusion s: Automated audiometry is valid for use as a method of hearing examination and monitoring in patients with multidrug-resistant tuberculosis.

Keywords: audiometry; multidrug-resistant tuberculosis; ototoxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoglycosides / therapeutic use
  • Antitubercular Agents / therapeutic use
  • Audiometry / methods
  • Cross-Sectional Studies
  • Hearing
  • Hearing Loss*
  • Humans
  • Retrospective Studies
  • Tuberculosis, Multidrug-Resistant* / diagnosis
  • Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

  • Aminoglycosides
  • Antitubercular Agents

Associated data

  • figshare/10.6084/m9.figshare.17129123